Financial markets focus on shareholder engagement as companies report results

By Newsdesk

March 02 2026
Share

In a week dominated by financial market developments and corporate announcements, companies are increasingly recognising the importance of shareholder engagement in driving market outcomes. The latest reporting season has underscored that market expectations and sentiment often outweigh financial results, with proactive companies continuing to outperform.

Financial markets focus on shareholder engagement as companies report results

The Capital Network's summary of the week highlights several key developments across various sectors, including major advancements in medical technology, industrial manufacturing, and pharmaceutical collaborations.

4DMedical's breakthrough in respiratory imaging

4DMedical (ASX:4DX) has achieved a significant milestone this year with the FDA clearance and CMS reimbursement of its CT:VQ™ technology. This innovative, non-contrast, CT-based ventilation-perfusion imaging technology is set to become a global standard of care in respiratory imaging. The technology's early adoption by leading U.S. academic medical centres, such as Stanford University and the Cleveland Clinic, demonstrates growing clinical confidence. "The FDA clearance marks a pivotal moment for us," said a company spokesperson. "We are seeing accelerating commercial momentum, especially through our North American partnership with Philips."

The company's operational expansion is evident, with its network growing to 430 SaaS sites worldwide and delivering over 151,000 scans in the first half of the year. The integration of AI capabilities through Imbio and ongoing regulatory progress in Canada, New Zealand, and Europe further bolster 4DMedical's global reach. "Our partnerships, like the one with AstraZeneca in Brazil, are crucial in advancing our population-scale ambitions," added the spokesperson.

AML3D's expansion into the US defence market

AML3D Limited (ASX:AL3), an Australian industrial group, continues to make strides in the U.S. defence market with its ARCEMY® systems. The company's H1 FY26 results reveal significant orders, with approximately A$16.5 million rolling from FY25 into the latest half. Of this, A$3.25 million was recognised as revenue, despite delays in raw material receipt. "Our U.S. Scale Up Strategy is gaining traction, with US-based customers accounting for 87% of our H1 FY26 revenues," said an AML3D spokesperson.

The company has also received a Letter of Intent from the US Navy, forecasting demand for 100 additive manufacturing systems by 2030. "This is just the beginning of our momentum in the U.S.," the spokesperson added. AML3D is also exploring opportunities in non-defence industrial markets and other regions, such as Europe, to broaden the market for its ARCEMY® systems.

Starpharma's profitable collaboration with Genentech

Starpharma (ASX: SPL, US OTC: SPHRY) has reported a strong first half for FY26, driven by a $10.8 million revenue, including an $8.3 million upfront payment from its collaboration with Genentech. The company posted a profit of $1.4 million for the period while investing $5.0 million in research and development. "Our collaboration with Genentech marks a significant step in advancing our DEP® HER2 radiopharmaceutical program," said a Starpharma representative.

The company also announced partnerships with Radiopharm Theranostics and progress in its Star Navigator program. "We are well-funded to execute our strategic priorities, with a closing cash balance of $18.2 million," the spokesperson noted. Starpharma's consumer health products, Viraleze™ and VivaGel® BV, continue to perform well, supporting the company's diversification strategy.

Optiscan Imaging's regulatory advancements

Optiscan Imaging Limited (ASX: OIL) is advancing its clinical and regulatory programs in preparation for US FDA submissions in 2026. The company is conducting clinical studies at several Australian hospitals and has unveiled three clinical platforms—InVue®, InForm®, and InSpecta®. "Our recent capital raise has secured a $17.75 million funding runway to progress our clinical trials," said an Optiscan spokesperson.

On the commercialisation front, Optiscan is preparing to launch InSpecta® into the veterinary market, refining its sales strategy with input from US-based consultants. "We showcased our device at major industry events, and the response has been overwhelmingly positive," the spokesperson added.

As companies continue to navigate the complexities of market expectations and financial performance, the emphasis on shareholder engagement and strategic partnerships remains a critical factor in driving success.

sections

most read

sections

most read

sections

most read

sections

most read

sections

most read

sections

most read

sections

most read

Most read

Age Pension increase prompts Australians to review their finances

Latest Podcast

Trust, technology and triage: what NSW’s ‘name and shame’ signals for real ...

Resources

There is $17.5 billion in lost and unclaimed super across ...

Invest